A meta-analysis of the influence of ADRB2 genetic polymorphisms on albuterol (salbutamol) therapy in patients with asthma
- PMID: 32986886
- DOI: 10.1111/bcp.14570
A meta-analysis of the influence of ADRB2 genetic polymorphisms on albuterol (salbutamol) therapy in patients with asthma
Abstract
Aims: The associations of 2 nonsynonymous single nucleotide polymorphisms (Arg16Gly and Gln27Glu) in the adrenoceptor β2 (ADRB2) gene with response after albuterol use are conflicting. We conducted a meta-analysis to examine the cumulative evidence of the effects of these 2 variants on percent forced expiratory volume in 1 second (FEV1.0%) after albuterol use in asthma patients.
Methods: We conducted a comprehensive literature search using MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials to identify studies examining the association between ADRB2 Arg16Gly and Gln27Glu and FEV1.0% shortly after albuterol administration. The individual study results were combined with weights based on the inverse variance method. This systematic review was registered in the PROSPERO (registration number: CRD42019074554).
Results: Among 273 initial studies identified, 7 studies met the inclusion criteria for quantitative evaluation. Results of the overall meta-analysis indicated no statistically significant mean difference of FEV1.0% between genotypes of Arg16Gly and Gln27Glu. In subgroup analyses, significant associations were found for Arg16Gly GG (vs AA) among studies where no methacholine bronchoconstriction was conducted (mean difference, -3.92; 95% confidence interval, -7.29 to -0.54; I2 = 0%), and for Arg16Gly GG (vs GA) among studies that included patients with no comorbidities (mean difference, -1.93; 95% confidence interval, -3.77 to -0.10; I2 = 0%).
Conclusion: Synthesis of the studies to date shows weak evidence for an association between ADRB2 Arg16Gly and Gln27Glu and FEV1.0% after albuterol use, results of which underscore significant heterogeneity across studies and the need for careful design and sample size considerations.
Keywords: ADRB2; albuterol; asthma; pharmacogenomics; polymorphisms; response.
© 2020 British Pharmacological Society.
Similar articles
-
Effect of ADRB2 (adrenergic receptor β2) gene polymorphisms on the occurrence of asthma and on the response to nebulized salbutamol in South Indian patients with bronchial asthma.J Asthma. 2015 Oct;52(8):755-62. doi: 10.3109/02770903.2015.1012589. Epub 2015 May 19. J Asthma. 2015. PMID: 25985706 Clinical Trial.
-
Relationship between polymorphisms in the 5' leader cistron, positions 16 and 27 of the adrenergic β2 receptor gene and asthma in a Han population from southwest China.Respirology. 2011 Nov;16(8):1221-7. doi: 10.1111/j.1440-1843.2011.02028.x. Respirology. 2011. PMID: 21801278
-
Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial.Lancet Respir Med. 2014 Jan;2(1):44-53. doi: 10.1016/S2213-2600(13)70248-0. Epub 2013 Dec 5. Lancet Respir Med. 2014. PMID: 24461901 Clinical Trial.
-
Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies.Lancet. 2007 Dec 22;370(9605):2118-25. doi: 10.1016/S0140-6736(07)61906-0. Lancet. 2007. PMID: 18156033 Review.
-
Association of arg16gly and gln27glu, b2-adrenergic receptor gene polymorphism with asthma. A systematic review and meta-analysis of case control studies.J Pak Med Assoc. 2018 Jan;68(1):90-97. J Pak Med Assoc. 2018. PMID: 29371726
Cited by
-
Exploring Factors Underlying Poorly-Controlled Asthma in Adults by Integrating Phenotypes and Genotypes Associated with Obesity and Asthma: A Case-Control Study.J Asthma Allergy. 2023 Jan 21;16:135-147. doi: 10.2147/JAA.S397067. eCollection 2023. J Asthma Allergy. 2023. PMID: 36714050 Free PMC article.
-
A review of recent advances in gene therapy, pharmacogenomics, and genetic polymorphisms in asthma.Mol Biol Rep. 2025 May 29;52(1):513. doi: 10.1007/s11033-025-10625-w. Mol Biol Rep. 2025. PMID: 40439783 Review.
-
Genetic Determinants of Poor Response to Treatment in Severe Asthma.Int J Mol Sci. 2021 Apr 20;22(8):4251. doi: 10.3390/ijms22084251. Int J Mol Sci. 2021. PMID: 33923891 Free PMC article. Review.
-
Grand challenges in genetics and epidemiology of allergic diseases: from genome to exposome and back.Front Allergy. 2024 Feb 5;5:1368259. doi: 10.3389/falgy.2024.1368259. eCollection 2024. Front Allergy. 2024. PMID: 38375070 Free PMC article. No abstract available.
References
REFERENCES
-
- U.S. Food and Drug Administration label PROAIR HFA (albuterol sulfate) INHALATION AEROSOL. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021457s026lbl.pdf. Accessed December 20, 2019.
-
- Anderson WJ, Short PM, Williamson PA, et al. Proof-of-concept evaluation of trough airway hyper-responsiveness following regular racemic or levosalbutamol in genotype-stratified steroid-treated persistent asthmatic patients. Clin Sci (Lond). 2014;126(1):75-83.
-
- Choudhry S, Ung N, Avila PC, et al. Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care Med. 2005;171(6):563-570.
-
- Giubergia V, Gravina LP, Castanos C, Chertkoff L, Grenoville M. Influence of beta2-adrenoceptor polymorphisms on the response to chronic use of albuterol in asthmatic children. Pediatr Pulmonol. 2008;43(5):421-425.
-
- Kukreti R, Bhatnagar P, B-Rao C, et al. Beta(2)-adrenergic receptor polymorphisms and response to salbutamol among Indian asthmatics*. Pharmacogenomics. 2005;6(4):399-410.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous